Core Viewpoint - The company, Fuhong Hanlin (02696.HK), has entered into a collaboration agreement with Aohong Pharmaceutical, granting exclusive commercialization rights for a product in a specified region and field [1] Group 1: Collaboration Agreement - The collaboration agreement was signed on December 3, 2025, following a memorandum of understanding established on August 7, 2025 [1] - The memorandum allowed the company to obtain exclusive commercialization rights for the licensed product in China during a transitional period before the formal agreement was signed [1] - The memorandum has been replaced by the collaboration agreement and automatically terminated on December 3, 2025 [1] Group 2: Licensed Product - The licensed product, citric acid voraselis capsule, is a CDK4/6 inhibitor approved for the treatment of HR+, HER2– breast cancer [1] - The product aligns with the company's commercialization strategy in the breast cancer sector and has commercial synergies with existing breast cancer pipeline products [1] - Introducing the licensed product will enrich the company's pipeline and enhance future revenue potential by leveraging the existing breast cancer commercialization team and resources [1]
复宏汉霖(02696.HK)就枸橼酸伏维西利胶囊与奥鸿药业订立合作协议